Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05633667 · ClinicalTrials.gov registry record · Phase 2
Study of Novel Treatment Combinations in Patients With Lung Cancer
A Phase 2 study of Lung Cancer and Advanced or Metastatic Non-Small-Cell Lung Cancer, sponsored by Gilead Sciences.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 270
- Enrollment target
- 20
- Study locations
NCT05633667 is a Phase 2 study of Lung Cancer and Advanced or Metastatic Non-Small-Cell Lung Cancer that is actively recruiting participants, run by Gilead Sciences. The registered enrollment target is 270 participants, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (71% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT05633667, a Phase 2 study of Lung Cancer and Advanced or Metastatic Non-Small-Cell Lung Cancer, is actively recruiting participants, sponsored by Gilead Sciences.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 270 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this platform clinical trial is to test how well novel treatment combinations work in participants with lung cancer. Substudy-01 will compare the different novel combinations versus standard of care in participants with metastatic (cancer that has spread) non-small-cell lung cancer (NSCLC) who have not been treated before. Substudy-02 will compare the different novel combination versus standard of care in participants with cancer that has progressed after receiving previous treatment for metastatic NSCLC. Substudy-03 will compare the different novel combinations versus standard of care in participants with resectable stage II-III NSCLC. The primary objectives of this study are: Substudy-01 and Substudy-02: To evaluate the objective response rate (ORR) assessed per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1). Substudy-03: To evaluate the efficacy of treatment combinations based on complete pathological response (pCR) rate.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Zimberelimab (ZIM)
- DRUG Domvanalimab (DOM)
- DRUG Sacituzumab govitecan-hziy (SG)
- DRUG Etrumadenant (ETRUMA)
Study Locations (20)
Missouri
- Washington University School of Medicine - Siteman Cancer Center,Substudy-01 - St Louis
- Washington University School of Medicine - Siteman Cancer Center,Substudy-02 - St Louis
- Washington University School of Medicine - Siteman Cancer Center,Substudy-03 - St Louis
- Washington University School of Medicine - Siteman Cancer Center - St Louis
Arizona
- Arizona Oncology Associates,Substudy-01 - Tucson
- Arizona Oncology Associates,Substudy-02 - Tucson
Colorado
- Rocky Mountain Cancer Center,Substudy-01 - Denver
- Rocky Mountain Cancer Center,Substudy-02 - Denver
Ohio
- Oncology Hematology Care Clinical Trials, LLC,Substudy-01 - Cincinnati
- Oncology Hematology Care Clinical Trials, LLC,Substudy-02 - Cincinnati
Oregon
- Oncology Associates of Oregon, PC,Substudy-01 - Eugene
- Oncology Associates of Oregon, PC,Substudy-02 - Eugene
Texas
- Texas Oncology - Central South,Substudy-01 - Austin
- Texas Oncology - Central South,Substudy-02 - Austin
Virginia
- US Oncology Investigational Products Center (IPC),Substudy-01 - Fairfax
- US Oncology Investigational Products Center (IPC),Substudy-02 - Fairfax
Washington
- Fred Hutchinson Cancer Center,Substudy-01 - Seattle
- Fred Hutchinson Cancer Center,Substudy-02 - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 270 participants |
| Start Date | 2023-03-16 |
| Est. Completion | 2029-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05633667
The ClinicalTrials.gov registry entry for NCT05633667 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 270 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (71% lower). The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT05633667 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Missouri, Arizona, Colorado.
Frequently Asked Questions
What is clinical trial NCT05633667 about?
NCT05633667 is a clinical study titled "Study of Novel Treatment Combinations in Patients With Lung Cancer". The goal of this platform clinical trial is to test how well novel treatment combinations work in participants with lung cancer. Substudy-01 will compare the different novel combinations versus standard of care in participants with metastatic (cancer that has spread) non-small-cell lung cancer (NSCL...
What is the current status of trial NCT05633667?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 270 participants. The study started on 2023-03-16. Estimated completion is 2029-09.
What conditions does trial NCT05633667 study?
This clinical trial studies the following conditions: Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer.
What interventions are being tested in trial NCT05633667?
The interventions under investigation include: Carboplatin (DRUG), Zimberelimab (ZIM) (DRUG), Domvanalimab (DOM) (DRUG), Sacituzumab govitecan-hziy (SG) (DRUG), Etrumadenant (ETRUMA) (DRUG).
Who is sponsoring clinical trial NCT05633667?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05633667 being conducted?
This trial has 20 study locations across Arizona, Colorado, Indiana, Kentucky, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®
RECRUITING · Phase 2
-
ATATcH Alternating Treatment Plans for Advanced Cancer
RECRUITING · Phase 2
-
A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
RECRUITING · Phase 2
-
Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.